Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who started this subject	3/18/2004 7:12:28 PM
From: mopgcw	of 590

GS CC replay info: Amgen Inc. EPS (FY Dec) 2004E $2.39, 2005E $2.84 Outperform/Neutral (AMGN) $61.30 Genentech Inc. EPS (FY Dec) 2004E $1.51, 2005E $1.90 Outperform/Neutral (DNA) $106.82 The Goldman Sachs Biotechnology Team will host a conference call Friday, March 19, at 10 AM EDT (Please note change from the regular time on Thursdays). Maykin Ho, Meg Malloy, and Stephen McGarry will discuss the following: (1) Amgen's analyst meeting on March 23, with a focus on the pipeline, including Abgenix's ABX-EGF (2) Approval of Raptiva (Serono/Genentech) in Switzerland (3) Update on Celltech. The call is for INSTITUTIONAL INVESTORS only. To participate, please dial 800-203- 4101 (US) or 703-563-6359 (Int 'l). Replay 800-615-3210 (US) or 703- 326-3020 (Int 'l), 5076453 (passcode).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next